# Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

> **NCT04413942** · PHASE2 · UNKNOWN · sponsor: **Oneness Biotech Co., Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** FB825
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04413942
- **Lead sponsor:** Oneness Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413942, "Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04413942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*